RaQualia Pharma Inc. (4579.T)
JPY 337.0
(0.9%)
JPY 337.0
(0.9%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.65 Billion JPY | -44.89% |
| 2022 | 2.68 Billion JPY | 9.4% |
| 2021 | 2.45 Billion JPY | 153.34% |
| 2020 | 969.28 Million JPY | -32.7% |
| 2019 | 1.44 Billion JPY | 119.84% |
| 2018 | 655.1 Million JPY | -48.4% |
| 2017 | 1.26 Billion JPY | 116.07% |
| 2016 | 587.6 Million JPY | 537.68% |
| 2015 | 92.14 Million JPY | -39.11% |
| 2014 | 151.34 Million JPY | -33.54% |
| 2013 | 227.73 Million JPY | 685.9% |
| 2012 | 28.97 Million JPY | -95.69% |
| 2011 | 672.77 Million JPY | -37.99% |
| 2010 | 1.08 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 542.9 Million JPY | 84.02% |
| 2024 Q2 | 549.59 Million JPY | 9.78% |
| 2023 Q4 | 295.02 Million JPY | -28.78% |
| 2023 FY | 1.48 Billion JPY | -44.89% |
| 2023 Q1 | 311.06 Million JPY | -67.26% |
| 2023 Q2 | 580.74 Million JPY | 86.69% |
| 2023 Q3 | 414.26 Million JPY | -28.67% |
| 2022 Q1 | 286.05 Million JPY | -74.03% |
| 2022 FY | 2.68 Billion JPY | 9.4% |
| 2022 Q4 | 950.13 Million JPY | 141.3% |
| 2022 Q3 | 393.75 Million JPY | -62.73% |
| 2022 Q2 | 1.05 Billion JPY | 269.34% |
| 2021 Q1 | 614.08 Million JPY | 24.55% |
| 2021 Q2 | 531.77 Million JPY | -13.4% |
| 2021 Q4 | 1.1 Billion JPY | 428.59% |
| 2021 Q3 | 208.35 Million JPY | -60.82% |
| 2021 FY | 2.45 Billion JPY | 153.34% |
| 2020 Q3 | 161.41 Million JPY | -25.63% |
| 2020 FY | 969.28 Million JPY | -32.7% |
| 2020 Q2 | 217.04 Million JPY | 121.98% |
| 2020 Q1 | 97.77 Million JPY | -89.1% |
| 2020 Q4 | 493.05 Million JPY | 205.46% |
| 2019 FY | 1.44 Billion JPY | 119.84% |
| 2019 Q3 | 127.65 Million JPY | -18.0% |
| 2019 Q4 | 897.41 Million JPY | 603.02% |
| 2019 Q1 | 259.42 Million JPY | 45.64% |
| 2019 Q2 | 155.67 Million JPY | -39.99% |
| 2018 FY | 655.1 Million JPY | -48.4% |
| 2018 Q4 | 178.12 Million JPY | 173.54% |
| 2018 Q1 | 377.42 Million JPY | -52.49% |
| 2018 Q2 | 34.43 Million JPY | -90.88% |
| 2018 Q3 | 65.11 Million JPY | 89.08% |
| 2017 Q1 | 304.17 Million JPY | 356.48% |
| 2017 FY | 1.26 Billion JPY | 116.07% |
| 2017 Q4 | 794.47 Million JPY | 491.09% |
| 2017 Q3 | 134.4 Million JPY | 267.25% |
| 2017 Q2 | 36.59 Million JPY | -87.97% |
| 2016 Q2 | 12.5 Million JPY | -97.43% |
| 2016 FY | 587.6 Million JPY | 537.68% |
| 2016 Q1 | 486.97 Million JPY | 456.73% |
| 2016 Q3 | 21.5 Million JPY | 72.0% |
| 2016 Q4 | 66.63 Million JPY | 209.93% |
| 2015 Q3 | 13.03 Million JPY | -59.9% |
| 2015 FY | 92.14 Million JPY | -39.11% |
| 2015 Q1 | 12.5 Million JPY | -65.12% |
| 2015 Q2 | 32.5 Million JPY | 160.0% |
| 2015 Q4 | 87.46 Million JPY | 571.24% |
| 2014 FY | 151.34 Million JPY | -33.54% |
| 2014 Q4 | 35.83 Million JPY | 59.26% |
| 2014 Q3 | 22.5 Million JPY | -68.97% |
| 2014 Q2 | 72.5 Million JPY | 253.49% |
| 2014 Q1 | 20.51 Million JPY | -81.4% |
| 2013 Q1 | 30.91 Million JPY | 6.67% |
| 2013 Q4 | 110.27 Million JPY | 220.9% |
| 2013 Q3 | 34.36 Million JPY | -32.87% |
| 2013 Q2 | 51.19 Million JPY | 65.61% |
| 2013 FY | 227.73 Million JPY | 685.9% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q1 | - JPY | -100.0% |
| 2012 FY | 28.97 Million JPY | -95.69% |
| 2012 Q4 | 28.97 Million JPY | 0.0% |
| 2012 Q2 | - JPY | 0.0% |
| 2011 Q3 | 61.11 Million JPY | 0.0% |
| 2011 FY | 672.77 Million JPY | -37.99% |
| 2011 Q4 | 9.57 Million JPY | -84.34% |
| 2011 Q1 | 602.08 Million JPY | 0.0% |
| 2011 Q2 | - JPY | -100.0% |
| 2010 FY | 1.08 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 11.968% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | -1962.298% |
| GNI Group Ltd. | 22.43 Billion JPY | 92.617% |
| Linical Co., Ltd. | 3.77 Billion JPY | 56.167% |
| Trans Genic Inc. | 2.24 Billion JPY | 26.369% |
| MEDINET Co., Ltd. | 98.25 Million JPY | -1585.614% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 33.284% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | -28.124% |
| AnGes, Inc. | -3.06 Billion JPY | 154.029% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 1031.897% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 82.863% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | -220.157% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | -1392.618% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | -14.17% |
| CanBas Co., Ltd. | -984 Million JPY | 268.308% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | -322.813% |
| Chiome Bioscience Inc. | 398.59 Million JPY | -315.497% |
| Kidswell Bio Corporation | 1.03 Billion JPY | -59.34% |
| PeptiDream Inc. | 17.21 Billion JPY | 90.382% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | -5311.367% |
| Ribomic Inc. | -10.5 Million JPY | 15869.844% |
| SanBio Company Limited | -14.5 Million JPY | 11518.567% |
| Healios K.K. | 108 Million JPY | -1433.471% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 485774.194% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 2904.845% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | 109633.664% |
| StemRIM | -44.34 Million JPY | 3834.355% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 48.002% |
| FunPep Company Limited | -680.28 Million JPY | 343.449% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -2291.551% |
| Stella Pharma Corporation | 217.29 Million JPY | -662.156% |
| TMS Co., Ltd. | -6.95 Million JPY | 23929.482% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | -426.495% |
| Cuorips Inc. | 9.63 Million JPY | -17096.023% |
| K Pharma,Inc. | 910 Million JPY | -81.994% |
| Takara Bio Inc. | 25.45 Billion JPY | 93.494% |
| ReproCELL Incorporated | 1.1 Billion JPY | -49.915% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | -38.583% |
| StemCell Institute Inc. | 1.57 Billion JPY | -5.093% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 0.638% |
| CellSeed Inc. | 107.15 Million JPY | -1445.564% |